Diabetes Care Growth Prospects Detailed By Abbott; Prism In Sight
This article was originally published in The Gray Sheet
Executive Summary
Abbott's diabetes care unit will develop into a $1 bil. business within the next two years, according to VP-Investor Relations John Thomas
You may also be interested in...
Hospira Assumes Responsibility For Recent Abbott Warning Letter
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets
Hospira Assumes Responsibility For Recent Abbott Warning Letter
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets
Abbott Acquires A Future For Its Diabetes Care Business; Where’s Bayer?
Access to a development partnership with insulin infusion pump manufacturer Smiths Medical could prove a critical component of Abbott Labs' $1.2 bil. purchase of diabetes management firm TheraSense